Donald Arents
Pulmonary Disease · Venice, FLNPI 1770655532
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $184,638 of the $194,013 with a category attached, or 95.2%. GSK accounts for 91.6% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $111,872 and has fallen 90.5% since, to $10,639 in 2022. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 225 payments — averaging $862.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$178K
- Mylan Specialty L.p.$16K
- AstraZeneca$362
- Boehringer Ingelheim$109
- Regeneron Healthcare Solutions, Inc.$65
- Takeda Pharmaceuticals U.S.A., Inc.$33
- plus $95 from 5 others
What the payments were for
- Consulting fees$2500%
- Speaking & faculty fees$184,63895%
- Travel & lodging$3,8602%
- Food & beverage$5,2653%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 163 | $177,759 |
| Mylan Specialty L.p. | 38 | $15,590 |
| AstraZeneca | 10 | $362 |
| Boehringer Ingelheim | 4 | $109 |
| Regeneron Healthcare Solutions, Inc. | 3 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Novartis | 1 | $23 |
| Merck | 1 | $21 |
| Gilead | 1 | $14 |
| Circassia Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$149,715
- Yupelri$14,841
- NUCALA$10,310
- ANORO$8,261
- ANORO ELLIPTA$7,428
- BREZTRI$236
How this compares
$194,013 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Venice
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.